Bimekizumab Not Linked to Depression, Suicidal Ideation in PsO Patients

The prescribing information for bimekizumab (Bimzelx, UCB) in the US includes a warning for suicidal ideation and behavior, and an increased incidence of new-onset or worsening suicidal ideation and behavior was observed among subjects treated with this drug in clinical trials. However, new research provides reassurance that bimekizumab does not confer additional psychiatric risks relative to other advanced biologics among people with psoriasis.
The study, published in JAAD International, analyzed nearly 3,800 adults using the TriNetX US Collaborative Network to compare rates of new-onset depression and suicidal ideation among patients treated with bimekizumab vs. interleukin (IL)-23 inhibitors.
The study’s primary outcome was new-onset depression. Patients with prior depression, major depressive disorder, suicidal ideation, or use of antidepressants and antipsychotics were excluded. Ultimately, 855 IL-23-treated and 836 bimekizumab-treated patients were included in the outcome analysis, forming the comparison groups for the study.
During follow-up, 12% of IL-23 users and 4.9% of bimekizumab users developed depression, suicidal ideation, or took an antidepressant or an antipsychotic.
Additionally, in a sensitivity analysis that restricted both cohorts to a uniform one-to-six-month post-index window, bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors. The six-month cumulative incidence of depression or suicidal ideation was 4.0% among IL-23 inhibitor users and 2.7% among bimekizumab users.
“Our findings suggest that bimekizumab is not associated with an increased risk of depression or suicidal ideation relative to IL-23 inhibitors in patients with psoriasis in real-world clinical settings,” conclude researchers from the George Washington University School of Medicine and Health Science in Washington, DC. “These data align with pooled clinical-trial safety results for both IL-17 and IL-23 pathways, where psychiatric events occur rarely and at rates consistent with background psoriasis populations.”
The study was not powered to show cause and effect. “Although causality cannot be inferred from observational data, the large multicenter dataset and robust matching strengthen confidence in these results,” the study authors note.
Routine mental health screening remains essential in patients receiving biologic therapy, they add.